Approval and initiation of clinical phase I/II study for the new COVID-19 vaccine developed by the team of Prof. Salanti
On March 8, AdaptVac announced that the clinical trial application (CTA) for a clinical phase I/II study for their ABNCoV2 COVID-19 vaccine has been approved by the Central Committee on Research Involving Human Subjects (CCMO), in the Netherlands. During the development process, the vaccine has been analyzed and validated using Attana’s QCM biosensor.AdaptVac initiates clinical phase I/II study for their new COVID-19 vaccineThe Central Committee on Research Involving Human Subjects (CCMM) in the Netherlands has approved the ABNCoV2 capsid virus-like particle (cVLP) based COVID-19 vaccine